Jack E. Ansell, MD
Jack E. Ansell, MD is the former Michael S. Bruno, MD, Chairman of Medicine at Lenox Hill Hospital and current Professor of Medicine at New York University School of Medicine. Dr. Ansell is a clinical investigator with a principal focus on the clinical problems of thrombosis, antithrombotic therapy, and the application of new modes of delivering and monitoring anticoagulants. He has authored more than 200 publications and has been the lead author for over 10 years of the major authoritative consensus guidelines for antithrombotic therapy through the American College of Chest Physicians. He is a Master of the American College of Physicians. Dr. Ansell received his medical degree from the University of Virginia and completed his medical residency at Tufts New England Medical Center followed by a fellowship in Hematology at Boston University.
Harvey Cantor, MD
Harvey Cantor, MD is Chair, Department of Cancer Immunology & AIDS and Baruj Benacerraf Professor of Microbiology and Immunobiology, Harvard Medical School. Dr. Cantor joined the Dana Farber Cancer Institute and Harvard faculty in 1974; since 1997, he has chaired the Department of Cancer Immunology and AIDS. He directed the DF/HCC Program in Cancer Immunology. He engages in teaching/training within the Harvard Medical School Graduate Program in Immunology and directs NIH postdoctoral training programs in AIDS research and cancer immunology. Dr. Cantor trained at the National Institutes of Health and National Institute for Medical Research in London. He received an MD from New York University in 1967 and completed residency in medicine at Stanford. In 2002, Dr. Cantor was elected to the U.S. National Academy of Sciences.
S. Thomas Emerson, PhD
S. Thomas Emerson, PhD is David T. and Lindsay J. Morgenthaler Professor of Entrepreneurship at the Carnegie Mellon Tepper School of Business. Dr. Emerson is an experienced entrepreneur, corporate executive, and educator. He founded and built three venture capital backed high technology companies: Periphonics Corporation, Syntellect Inc., and Xantel Corporation. Two of these companies (Periphonics and Syntellect) became NASDAQ-listed national market companies. They created in aggregate more than $600 million in shareholder value. Dr. Emerson was named Inventor of the Year by the U.S. Patent Office in 1973. Prior to joining Carnegie Mellon, he was President and CEO of Arizona Technology Incubator, a public-private partnership in Scottsdale, Arizona that mentors promising young technology companies.
Robert S. Langer, Jr. ScD
Dr Robert Langer is a leading bioengineer and entrepreneur. He is one of 11 Institute Professors at the Massachusetts Institute of Technology, the highest honour that can be awarded to a faculty member. Prior to this role, he was the Germeshausen Professor of Chemical and Biomedical Engineering. Langer is an internationally acclaimed inventor and engineer, with over 2000 patents and published articles. His research focuses on the field of bioengineering. He was one of the first chemical engineers to work in the surgical sector, becoming a pioneer in drug delivery, tissue engineering, and nanotechnology. Langer’s research laboratory at MIT is the largest academic biomedical engineering lab in the world, maintaining over $15 million in annual grants and over 100 researchers. Langer is also currently on the board of directors at Bind Therapeutics and Advanced Cell Technology.
Michele Mercuri, MD
Michele F. Mercuri, MD, PhD, FAHA, FESC, is a physician scientist professionally devoted to fostering the discovery, research, translation and development of innovative diagnostic, prophylactic, and therapeutic medical tools. A former Daiichi Sankyo Sr. Vice President, Dr. Mercuri led the development of edoxaban—an oral, direct factor Xa inhibitor. Dr. Mercuri served as the Global Head for cardio, vascular, metabolic and renal disease Therapeutic Area for translational sciences and clinical development, Chief Medical Advisor to the Head of Development, and Head of Clinical Development for the Americas. Dr. Mercuri graduated in medicine and surgery from the University of Perugia (Italy), and trained in Internal and Geriatric Medicine at the Universities of Parma (Italy) and Modena (Italy). A fellow in Cerebrovascular Disease and Vascular Ultrasound at the Bowman Gray School of Medicine at Wake Forest University (Winston-Salem, NC, USA), Dr. Mercuri served on the Medical School Faculty and as the Co-Director of the Division of Vascular Ultrasound. Dr. Mercuri joined the Pharmaceutical Industry with Merck Research Laboratory (Rahway, NJ, USA) in 1996 and worked on a wide range of cardiometabolic drugs in all phases of research and development. In 2003, Dr. Mercuri moved to Novartis Pharmaceuticals’ Clinical Development & Medical Affairs (East Hanover, NJ, USA) to lead Cardiometabolic Disease and Atherosclerosis drug development prior to assuming leading positions within the Methodology and Innovation Global Development group, and in the Division of Hematology and Oncology. Dr. Mercuri published over 100 articles in peer-reviewed medical and scientific journals in collaboration with leading scientists from around the world.